Tsuda S

References (4)

Title : Crystal structure and enhanced activity of a cutinase-like enzyme from Cryptococcus sp. strain S-2 - Kodama_2009_Proteins_77_710
Author(s) : Kodama Y , Masaki K , Kondo H , Suzuki M , Tsuda S , Nagura T , Shimba N , Suzuki E , Iefuji H
Ref : Proteins , 77 :710 , 2009
Abstract : The structural and enzymatic characteristics of a cutinase-like enzyme (CLE) from Cryptococcus sp. strain S-2, which exhibits remote homology to a lipolytic enzyme and a cutinase from the fungus Fusarium solani (FS cutinase), were compared to investigate the unique substrate specificity of CLE. The crystal structure of CLE was solved to a 1.05 A resolution. Moreover, hydrolysis assays demonstrated the broad specificity of CLE for short and long-chain substrates, as well as the preferred specificity of FS cutinase for short-chain substrates. In addition, site-directed mutagenesis was performed to increase the hydrolysis activity on long-chain substrates, indicating that the hydrophobic aromatic residues are important for the specificity to the long-chain substrate. These results indicate that hydrophobic residues, especially the aromatic ones exposed to solvent, are important for retaining lipase activity.
ESTHER : Kodama_2009_Proteins_77_710
PubMedSearch : Kodama_2009_Proteins_77_710
PubMedID: 19544571
Gene_locus related to this paper: crysp-Q874E9

Title : Alternate conformations observed in catalytic serine of Bacillus subtilis lipase determined at 1.3 A resolution - Kawasaki_2002_Acta.Crystallogr.D.Biol.Crystallogr_58_1168
Author(s) : Kawasaki K , Kondo H , Suzuki M , Ohgiya S , Tsuda S
Ref : Acta Crystallographica D Biol Crystallogr , 58 :1168 , 2002
Abstract : Bacillus subtilis extracellular lipase (BsL) has an exceptionally low molecular weight (19.4 kDa) for a member of the lipase family. A crystallographic study was performed on BsL in order to design and produce mutant BsL that will be more suitable for industrial uses based on analysis of the three-dimensional structure. Recently, the crystal structure of BsL has been determined at 1.5 A resolution [van Pouderoyen et al. (2001). J. Mol. Biol. 309, 215-226]. In the present study, a new crystal form of BsL which provides diffraction data to higher resolution was obtained and its structure was determined at 1.3 A using the MAD method. It was found that the active-site residue Ser77 has alternate side-chain conformations. The O(gamma) atom of the first conformer forms a hydrogen bond to the N(epsilon) atom of His155, a member of the catalytic triad. In contrast, the second conformer is constructed with a hydrogen bond to the side-chain atom of the adjacent His76. These two conformers presumably correspond to the active and inactive states, respectively. Similar alternate conformations in the catalytic serine residue have been observed in Fusarium solani cutinase determined at 1.0 A resolution and Penicillium purpurogenum acetylxylan esterase at 0.9 A resolution. In addition, a glycerol molecule, which was used as a cryoprotectant, is found to be located in the active site. On the basis of these results, a model for substrate binding in the reaction-intermediate state of BsL is proposed.
ESTHER : Kawasaki_2002_Acta.Crystallogr.D.Biol.Crystallogr_58_1168
PubMedSearch : Kawasaki_2002_Acta.Crystallogr.D.Biol.Crystallogr_58_1168
PubMedID: 12077437
Gene_locus related to this paper: bacsu-lip

Title : The neurotrophic effects of ebiratide, an analog of ACTH4-9, on cultured septal cells and aged rats - Matsumoto_1995_J.Neur.Transm_100_1
Author(s) : Matsumoto T , Tsuda S , Nakamura S
Ref : Journal of Neural Transmission General Section , 100 :1 , 1995
Abstract : The neurotrophic effects of ebiratide, an ACTH4-9 analog, have been examined using both fetal rat septal cultures and aged rats. The 5-day treatment with ebiratide (10-100 pmol/ml) partially prevented neuronal degeneration that occurred in the cultures in which cells were sparsely plated. Ebiratide (10 pmol/ ml) increased choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities up to 1.5 and 1.2 times the respective control values in the sub-confluent cultures. AChE cytochemistry of the cultures has shown that ebiratide increased the stained area per cell. Ebiratide subcutaneously administered by constant infusion (10 nmol/body/hr) for 4 weeks elevated ChAT activities in the septum (35% over control), neocortex (79%) and hippocampus (89%) of aged rats. Thus, the present study indicates that ebiratide shares neurotrophic properties which may prove beneficial in the therapy for CNS degenerative disorders, especially Alzheimer's disease.
ESTHER : Matsumoto_1995_J.Neur.Transm_100_1
PubMedSearch : Matsumoto_1995_J.Neur.Transm_100_1
PubMedID: 8748659

Title : Pretreatment of rats with an organophosphorus insecticide, chlorfenvinphos, protects against subsequent challenge with the same compound - Ikeda_1990_Fundam.Appl.Toxicol_14_560
Author(s) : Ikeda T , Kojima T , Yoshida M , Takahashi H , Tsuda S , Shirasu Y
Ref : Fundamental & Applied Toxicology , 14 :560 , 1990
Abstract : A single oral pretreatment of rats with chlorfenvinphos (CVP) reduced toxicity of the same compound subsequently administered. This protection occurred 8 hr and became maximal 24 hr after the oral pretreatment at a dose of 15 mg/kg (about half of its LD50). The 24-hr pretreatment with CVP increased the LD50 of CVP threefold, but did not change the type of toxic signs and time to death caused by CVP. The CVP pretreatment did not appreciably change the toxicities of the cholinergic agonists, carbachol and oxotremorine, but significantly increased the toxicity of another organophosphate, dichlorvos. Oral treatment of rats with CVP (15 mg/kg) inhibited brain acetylcholinesterase (AChE) activity. This inhibition became maximal at 4 hr (about 20% of control) and lasted more than 24 hr after the administration. Twenty-four hours after oral administration of CVP (15 mg/kg), the second dose (CVP 30 mg/kg, po) was less effective in inhibiting cholinesterase activities of the brain, erythrocyte, and plasma compared with naive rats treated with the same dose. The difference in brain AChE activity between control and CVP pretreatment groups was greater in magnitude than that measured in erythrocytes. CVP concentration in plasma after the oral administration of CVP (30 mg/kg) was decreased by the CVP pretreatment. Area under the concentration vs time curve (AUC) in the CVP-pretreated group was about one-fourth of AUC in the control group. This decrease in the AUC was comparable to the decrease in the toxicity of CVP. Thus, the protection against subsequent CVP challenge may be due to the reduction in the inhibition of brain AChE activity caused by the decrease in plasma CVP concentration.
ESTHER : Ikeda_1990_Fundam.Appl.Toxicol_14_560
PubMedSearch : Ikeda_1990_Fundam.Appl.Toxicol_14_560
PubMedID: 2340983